Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

University of Bristol

- PMLiVE

Merck hopes for another Keytruda with new immunotherapy deal

US firm signs pact with cCAM Biotherapeutics for cancer research

- PMLiVE

Type 2 diabetes market set to hit $39bn by 2021

Grwoth expected to come from new treatments and the condtion's rising prevalence

- PMLiVE

Novo Nordisk’s next-gen GLP-1 aces late-stage trial

Firm hopes semaglutide will shore up future sales of its diabetes range

- PMLiVE

Medtronic and Samsung partner on diabetes device

Alliance will develop app to monitor glucose and insulin information

- PMLiVE

Novo pulls Tresiba from Europe’s biggest market

Firm’s new insulin will not be sold in Germany

- PMLiVE

AstraZeneca and its diabetes plans

Director of marketing Chris Boulton is bullish on its prospects

- PMLiVE

AZ and Inserm collaborate on diabetes and kidney disease

Three-year partnership will look at new therapeutic approaches

- PMLiVE

Novo Nordisk becomes diabetes drug sales leader

Supplants former frontrunner Sanofi - but both firms set for a tough 2015

- PMLiVE

Bayer sells diabetes division to Panasonic Healthcare

€1.02bn sale includes Contour electronic meters and other medical devices

- PMLiVE

Sanofi will resubmit Lyxumia for FDA approval in Q3

Follows the GLP-1 agonist's all-clear by ELIXA cardiovascular safety study

- PMLiVE

Merck & Co’s diabetes drug Januvia cleared by CV safety trial

Concerns over the DPP-4 inhibitor 'put to bed' by TECOS cardiovascular trial

- PMLiVE

Atlantis Healthcare win grant for patient support programme

Programme will support chronic kidney disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links